Logo

Aldeyra's ADX-2191 Receives FDA's Fast Track Designation to Prevent Proliferative Vitreoretinopathy

Share this

Aldeyra's ADX-2191 Receives FDA's Fast Track Designation to Prevent Proliferative Vitreoretinopathy

Shots:

  • The US FDA has granted FT designation to ADX-2191 for the prevention of proliferative vitreoretinopathy and provides it eligibility for Priority Review and rolling NDA submission
  • The FDA’s FT designation facilitates the development and expedites the review of drugs that treat serious conditions- potentially accelerating patient access to new therapies
  • ADX-2191 is an intravitreal formulation of methotrexate and has received FDA’s ODD for preventing PVR with its expected onset of P-III GUARD Trial in Q4’19. The study will evaluate recurrence rates of PVR-related retinal detachment in patients treated with ADX-2191 or SoC following surgical repair of retinal detachment

Click here to­ read full press release/ article | Ref: Aldeyra | Image: Aldeyra


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions